Understanding COVID-19 Mechanisms 2021
DOI: 10.1136/thorax-2021-btsabstracts.62
|View full text |Cite
|
Sign up to set email alerts
|

S56 Measures of inflammation, complement activation and coagulation in patients with COVID-19

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
1
0
1

Year Published

2022
2022
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
1
0
1
Order By: Relevance
“…Promising preclinical effects have now been shown in a preclinical model of bullous pemphigoid [202]. Similarly, nomacopan is being developed against exuberant pulmonary inflammation in COVID‐19, in which elevated plasma levels of leukotriene B4 and complement factor 5a have been detected [203]. Clinical trials have been announced [204], but no data have been published in this indication.…”
Section: Immunomodulationmentioning
confidence: 99%
“…Promising preclinical effects have now been shown in a preclinical model of bullous pemphigoid [202]. Similarly, nomacopan is being developed against exuberant pulmonary inflammation in COVID‐19, in which elevated plasma levels of leukotriene B4 and complement factor 5a have been detected [203]. Clinical trials have been announced [204], but no data have been published in this indication.…”
Section: Immunomodulationmentioning
confidence: 99%
“…In einem präklinischen Modell des Bullösen Pemphigoids wurden inzwischen erfolgversprechende präklinische Wirkungen gezeigt [202]. Ebenso wird Nomacopan gegen überschießende pulmonale Entzündungen bei COVID-19, bei denen erhöhte Plasmaspiegel von Leukotrien B4 und Komplementfaktor 5a gemessen wurden [203], entwickelt. Klinische Studien wurden angekündigt [204], aber in dieser Indikation wurden noch keine Daten publiziert.…”
Section: Immunmodulationunclassified